budesonide + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Seasonal Allergic Rhinitis

Conditions

Seasonal Allergic Rhinitis

Trial Timeline

Apr 1, 2002 → Aug 1, 2002

NCT ID

NCT00641979

About budesonide + Placebo

budesonide + Placebo is a phase 2 stage product being developed by AstraZeneca for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00641979. Target conditions include Seasonal Allergic Rhinitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01136382	Phase 2	Completed	Jul 1, 2010	Apr 1, 2013	Asthma
NCT00642187	Phase 3	Completed	Jul 1, 2002	Oct 1, 2004	Asthma
NCT00641979	Phase 2	Completed	Apr 1, 2002	Aug 1, 2002	Seasonal Allergic Rhinitis
NCT00641212	Approved	Completed	Jan 1, 2000	Apr 1, 2003	Perennial Allergic Rhinitis
NCT00641914	Approved	Completed	Oct 1, 1996	Feb 1, 2003	Asthma

Competing Products

20 competing products in Seasonal Allergic Rhinitis

See all competitors

Product	Company	Stage	Hype Score
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	77
ASP4070 + Placebo	Astellas Pharma	Phase 2	52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)	Glenmark Pharmaceuticals	Phase 2	52
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray	Glenmark Pharmaceuticals	Phase 2	52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placebo	Johnson & Johnson	Phase 1	33
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + Placebo	AstraZeneca	Phase 2	52
Ciclesonide + Placebo	AstraZeneca	Phase 3	77
Ciclesonide Nasal Spray	AstraZeneca	Phase 3	77
Budesonide + Fluticasone propionate + Placebo	AstraZeneca	Phase 3	77
Ciclesonide + Ciclesonide Placebo	AstraZeneca	Phase 3	77
loratadine	Merck	Pre-clinical	23
MK0524	Merck	Phase 2	52
loratadine; montelukast	Merck	Phase 3	77

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved